Singapore
Hummingbird Bioscience, founded in 2015 and headquartered in Singapore, is making significant strides in the biotechnology sector. As a precision biotherapeutics company, Hummingbird Bioscience focuses on discovering and developing transformative biologics for hard-to-treat diseases. Integrating computational and systems biology with wet lab drug discovery, the company operates within a multidisciplinary, collaborative framework that extends from initial discovery to clinical development.
The company's approach combines target identification with patient selection, enhancing the efficiency of translating novel scientific insights while reducing risks in drug discovery. Hummingbird Bioscience embodies a commitment to rigorous science, teamwork, and intellectual integrity, aiming to accelerate the development of new drugs from concept to clinic.
In 2021, Hummingbird Bioscience secured a $125 million Series C investment led by notable investors including Novo Holdings, Amgen Ventures, EDBI, and others, demonstrating strong confidence in their innovative approach.
